We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mechanically ventilated patients with COVID-19 were 44 percent less likely to die when Olumiant (baricitinib) was added to the standard treatment regimen, according to a substudy of Eli Lilly’s COV-BARRIER trial. Read More
The drugmaker projected that a third dose could yield a 100-fold increase in neutralization of the Delta variant when compared against the two-dose regimen. Read More
Axon Neuroscience’s investigational anti-tau antibody treatment for Alzheimer’s disease, AADvac1, has posted positive phase 2b results, reducing cognitive slowing by up to 30 percent and neurodegeneration by 62 percent compared to placebo in patients with biomarker-confirmed disease. Read More
Given concerns about the rapidly spreading Delta variant, an eight-week window was deemed preferable by the researchers from Oxford and Newcastle universities. Read More
The real-world analysis comprised nearly 70,000 individuals who contracted the SARS-CoV-2 virus from December 2020 to May 2021 in the province of Ontario. Read More
The latest study to look at biopharma sponsors’ trial transparency performance shows that while several big-name companies are meeting their obligations to share trial results with other researchers and the public, smaller firms are struggling. Read More
The research suggests that a second vaccine dose may be necessary for those vaccinated with the single-dose J&J shot, the NYU researchers said. Read More